Group 1 - The stock of Qianxin Biopharmaceuticals-B (02509) rose over 8% during trading, reaching a new high of 22.15 HKD, with a cumulative increase of nearly 40% in the past month [1] - Qianxin Biopharmaceuticals focuses on biopharmaceutical therapies for autoimmune and allergic diseases, with a fully self-developed drug pipeline and mature commercial-scale production capabilities [1] - The company has a diverse product pipeline, including one product approved for market, two in Phase III clinical trials, and four in Phase II and I trials, targeting diseases such as psoriasis, atopic dermatitis, ankylosing spondylitis, systemic lupus erythematosus, asthma, and inflammatory bowel disease [1] Group 2 - In April, Qianxin Biopharmaceuticals signed a licensing agreement with Caldera Therapeutics for its long-acting dual antibody QX030N, granting Caldera global exclusive rights for development and commercialization [2] - The agreement provided Qianxin Biopharmaceuticals with a one-time payment of 10 million USD, approximately 24.88% equity in Caldera, and potential additional payments up to 545 million USD under specific conditions, along with tiered royalties on net sales [2] - The company expects significant revenue from its biosimilar product, Sailixin, which has entered the medical insurance directory, with projected sales of 300 million RMB in 2025 and peak sales of 1.5 billion to 2 billion RMB [2]
港股异动 | 荃信生物-B(02509)盘中涨超8% 近一个月股价累涨近四成 自免双抗布局国内领先